17 April 2024
EMA/CAT/128490/2024
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 13-15 March 2024

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair welcomed the new members and alternates and thanked the departing members/alternates for their contributions to the Committee.

The EMA secretariat announced the names of the Committee members who delegated their vote via proxy and the Committee members who received such proxy.

1.2. Adoption of agenda

The CAT agenda for 13-15 March 2024 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 14-16 February 2024 meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Fidanacogene elaparvovec - PRIME - EMEA/H/C/004774

Indicated for the treatment of severe and moderately severe haemophilia B

Scope: Day 180 list of outstanding issues

Action: for adoption

List of questions adopted on 08.09.2023.

The Rapporteurs presented the assessment of the responses to the list of questions.

CAT adopted the list of outstanding issues.

2.4. Day 120 list of questions

2.4.1. Beremagene geperpavec - PRIME - Orphan - EMEA/H/C/006330

Krystal Biotech Netherlands B.V.; Treatment of patients from birth with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

Scope: Day 120 list of questions

Action: for adoption

The Rapporteurs presented the outcome of the assessment of the application. A list of questions was adopted.

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. Companion diagnostics

2.10.1. Initial consultation

No items

2.10.2. Follow-up consultation

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/II/0037/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, request for supplementary information

Action: for adoption

The request for supplementary information was adopted.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/REC/015.1

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini

Scope: Quality, opinion

Action: for adoption

The outcome of the assessment was adopted.

2.13.2. Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - EMEA/H/C/004731/REC/018

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini

Scope: Quality, request for supplementary information

Action: for adoption

The outcome of the assessment was adopted. This post-authorisation measure is not fulfilled.

2.13.3. ROCTAVIAN - Valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/ANX/002.2

BioMarin International Limited

Rapporteur: Violaine Closson Carella, CHMP Coordinator: Jean-Michel Race

Scope: Clinical, opinion

Annual Status Report - Study Protocol 270-601 [A Non-Interventional, Multi- National, Longitudinal Study of Patients Treated with Roctavian (valoctocogene roxaparvovec)].

Action: for adoption

The outcome of the assessment was adopted. This post-authorisation measure is not fulfilled.

2.13.4. ROCTAVIAN - Valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/ANX/004.2

BioMarin International Limited

Rapporteur: Violaine Closson Carella, CHMP Coordinator: Jean-Michel Race

Scope: Clinical, opinion

Annual Registry - Study 270-801 [A Retrospective Cohort Study of Patients Treated with Roctavian (valoctocogene roxaparvovec): An Analysis of Patient Registries].

Action: for adoption

The outcome of the assessment was adopted. This post-authorisation measure is not fulfilled.

2.13.5. Zolgensma - Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/P46/023

Novartis Europharm Limited

Rapporteur: Emmely de Vries, CHMP Coordinator: Peter Mol

Scope: Clinical, request for supplementary information

Paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended.

Clinical study report of Study No. COAV101A1IC01 (OFELIA) [Phase IV Open-label, single-arm, single-dose, multicentre study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101(AVXS101) in paediatric patients from Latin America with spinal muscular atrophy (SMA)].

Action: for adoption

The outcome of the assessment was adopted. This post-authorisation measure is not fulfilled.

2.14. GMP and GCP inspections requests

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

Timetable:

-Start of the procedure:	25.03.2024
-EMA Coordinator's draft report:	02.04.2024
-CAT Coordinator's comments:	10.04.2024
-Revised scientific recommendation:	12.04.2024
-CAT's discussion of scientific recommendation:	19.04.2024

4.1. New requests – Appointment of CAT Coordinator

4.1.1. mRNA encoding ARCUS nuclease

For treatment of chronic hepatitis B (CHB) virus infection

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.2. Allogeneic human corneal endothelial cells (neltependocel) and a low molecular weight Rho kinase inhibitor (Y-27632)

For treatment of corneal oedema due to corneal endothelial dysfunction

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.3. Lymphocyte concentrate

For improvement of the pregnancy outcomes among women with unexplained repeated pregnancy loss and HLA sharing among partners

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Allogeneic human induced pluripotent stem cells-derived corneal limbal stem cells

For treatment of limbal stem cell deficiency

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.05.2024.

4.2.2. Olfactory glial cells isolated from autologous human olfactory bulb, expanded in culture

For treatment of complete spinal cord injuries

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.05.2024.

4.2.3. Circular RNA capable to bind to mutated regions of the messenger RNA from the DMPK gene

For treatment of myotonic dystrophy type 1

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 02.05.2024.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Modified measles vaccine virus

For the treatment of solid cancer tumours

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) No. 1394/2007.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	04-07.03.2024
- Appointment of CAT Peer Reviewers:	13-15.03.2024
- SAWP first reports:	02.04.2024
- CAT Peer Reviewer comments (NC/C):	05.04.2024
- CAT Peer Reviewer comments (Q):	10.04.2024
- Discussion at SAWP:	08-11.04.2024
- Discussion at CAT and feedback to SAWP:	17-19.04.2024

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	08-11.04.2024
- Appointment of CAT Peer Reviewers:	17-19.04.2024
- SAWP first reports:	06.05.2024

- CAT Peer Reviewer comments (NC/C):	10.05.2024
- CAT Peer Reviewer comments (Q):	15.05.2024
- Discussion at SAWP:	13-16.05.2024
- Discussion at CAT and feedback to SAWP:	22-24.05.2024

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:	
Procedure start:	04-07.03.2024
SAWP recommendation:	11.04.2024
CAT recommendation:	19.04.2024
CHMP adoption of report and final recommendation:	25.04.2024

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

The chair welcomed Denisa Marilena Margina and Liviu Nitulescu, as the new member and alternate for Romania.

The chair welcomed Alessia Pochesci and Nancy de Bremaeker as the new member and alternate for Luxembourg.

The chair thanked Silviu Istrate and Alexandrina Preda for their contributions as member and alternate for Romania.

7.1.2. Vote by proxy

Una Riekstina (Latvia) gave a proxy vote to Heli Suila (Finland) to vote on her behalf during the entire meeting.

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Belgian presidency – 15-17 May 2024

CAT: Claire Beuneu

Scope: Draft agenda of the upcoming SRLM

Action: for discussion

The agendas of the CAT SRLM and the CAT-PDCO SRLM meeting were presented. The official invitation to the meeting will be sent shortly.

7.2. Coordination with EMA Scientific Committees

7.2.1. EU NTC training webinar on the regulatory/HTA interface under the HTA Regulation

Scope: Presentation on the upcoming EU NTC training webinar on the regulatory/HTA interface to take place on 02.05.2024

Action: for information

The information on the upcoming EU NTC training webinar was noted. This training will be virtual and recorded.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Workshop - Challenges in drug development, regulation and clinical practice in hemoglobinopathies

Scope: Presentation on the draft agenda of the workshop to take place on 01.07.2024

Action: for discussion

The information on the workshop was noted. This will be a virtual meeting.

7.3.2. Revision of the Variations Framework

Scope: Presentation on the main points of the proposal

Action: for discussion

EMA presented the main points of the proposal for the revision of the variation guideline. CAT members were invited to comment on the proposals made for biological medicinal products .

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Ilona Reischl

Scope: Feedback from the teleconference of 22.02.2024

Action: for information

The feedback from the last ATMP cluster TC was noted.

7.5.2. International Pharmaceutical Regulatory Programme (IPRP) Gene and Cell therapy working group

CAT: Pille Säälik

Scope: Feedback from the teleconference of 27.02.2024

Action: for information

The feedback from the last IPRP GCWG was noted.

7.5.3. ICH Cell and Gene Therapy Discussion Group

CAT: Jan Müller-Berghaus, Andreea Barbu

Scope: To collect input from CAT on how to address a request for feedback from the ICH Cell and Gene Therapy Discussion Groups.

Action: for discussion

The activities from the ICH cell and gene therapy discussion group were presented. CAT members were specifically asked to identify, from their experience, areas where there is divergence between authorities or 'pain points' in the assessment where there are divergencies between the regulators and the developers. Feedback can be provided from both clinical trial and MA approvals. CAT members were invited to send their feedback to the EU coordinators (Jan Müller-Berghaus, Andreea Barbu) or the CAT secretariat.

7.6. CAT work plan

7.6.1. Guideline on quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials

CAT: Ilona Reischl

Scope: Adopted guideline, for release of a second public consultation

Action: for information

Following comments received from CTCG and NCA, final amendments were made to the guideline text. The guideline was adopted by CAT on 08.03.24 via a written procedure and by CHMP during their PROM meeting on 11.03.24. The Guideline will now be published on the EMA website for a short second public consultation until end of May 2024.

7.7. Planning and reporting

7.7.1. Business Pipeline Report

Scope: Q1/2024 Update of the Business Pipeline report for the human scientific committees

Action: for information

The business pipeline report for 2024 was presented.

7.8. Others

No items

8. Any other business

No items

Date of next CAT meeting:

17-19 April 2024

9. List of participants

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 13-15 March 2024 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ilona Reischl	Chair	Austria	No interests declared	
Silke Dorner	Member	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Olga Kholmanskikh	Alternate	Belgium	No interests declared	
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Evelina Shumkova	Alternate	Bulgaria	No interests declared	
Azra Selimovic	Member	Croatia	No interests declared	
Rafaella Pontou	Member	Cyprus	No interests declared	
Isavella Kyriakidou	Alternate	Cyprus	No interests declared	
Petr Soukup	Member	Czechia	No interests declared	
Kristyna Rehorova Hradilkova	Alternate	Czechia	No interests declared	
Ebru Karakoc Madsen	Member	Denmark	No interests declared	
Bibi Fatima Syed Shah	Alternate	Denmark	No interests declared	
Toivo Maimets	Member	Estonia	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Violaine Closson Carella	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Jan Mueller-Berghaus	Member (CHMP co-opted member)	Germany	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maria Gazouli	Member	Greece	No interests declared	
Angeliki Rompoti	Alternate	Greece	No restrictions applicable to this meeting	
Viola Bardoczy	Alternate	Hungary	No interests declared	
Joseph De Courcey	Member	Ireland	No interests declared	
Richard Carroll	Alternate	Ireland	No interests declared	
Concetta Quintarelli	Member	Italy	No interests declared	
Barbara Bonamassa	Alternate	Italy	No interests declared	
Villma Perikaite	Member (CHMP member)	Lithuania	No interests declared	
Raimondas Benetis	Alternate (to CHMP representative)	Lithuania	No interests declared	
Vlasta Zavadova	Member	Liechtenstein	No interests declared	
Alessia Pochesci	Member	Luxembourg	No restrictions applicable to this meeting	
Nancy De Bremaeker	Alternate	Luxembourg	No interests declared	
John J. Borg	Member (CHMP member)	Malta	No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Emmely de Vries	Member	Netherlands	No interests declared	
Berendina Maria (Tineke) van den Hoorn	Alternate	Netherlands	No interests declared	
Rune Kjeken	Member	Norway	Cannot act as rapporteur, other leading/co-ordinating role or peer reviewer on:	3.3.1.
Dariusz Sladowski	Member	Poland	No restrictions applicable to this meeting	
Maria Isabel Borba Vieira	Alternate (to CHMP representative)	Portugal	No interests declared	
Liviu Nitulescu	Alternate	Romania	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Margareta Fogelová	Alternate	Slovakia	No interests declared	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Suzana Vidic	Alternate	Slovenia	No participation in discussion, final deliberations and voting on:	2.13.5. Zolgensma P46/23
Sol Ruiz	Member (CHMP co-opted member)	Spain	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Maria Luttgen	Member	Sweden	No restrictions applicable to this meeting	
Charlotte Anderberg	Alternate	Sweden	No interests declared	
Bernd Gansbacher	Alternate	Clinicians' Representative	No interests declared	
Paolo Gasparini	Member	Clinicians' Representative	No interests declared	
Kieran Breen	Member (Vice-Chair)	Patients' Representative	No interests declared	
Daniela Philadelphy	Expert	Austria	No interests declared with information under any other interests	2.3.1. - Fidanacogene elaparvovec - PRIME
Brigitte Müller	Expert	Austria	No interests declared with information under any other interests	2.3.1. - Fidanacogene elaparvovec - PRIME
Sean Barry	Expert	Ireland	Indirect interests declared	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Caoimhin Concannon	Expert	Ireland	No interests declared	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Dana Gabriela Marin	Expert	Romania	No interests declared	6.1.1.
Pauliina Lehtolainen-Dalkilic	Expert	Finland	No interests declared	6.1.1.
Marie Louise Schougaard Christiansen	Expert	Denmark	No interests declared	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Juliane Rau	Expert	Germany	No interests declared with information under any other interests	2.3.1. - Fidanacogene elaparvovec - PRIME

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Beate Mosl	Expert	Germany	No interests declared	2.3.1. - Fidanacogene elaparvovec - PRIME
Federico De Angelis	Expert	Italy	No interests declared	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Pia Rivetti di Val Cervo	Expert	Italy	No interests declared	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Elma O'Reilly	Expert	Ireland	No interests declared	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Emma Fagan	Expert	Ireland	No interests declared with information under any other interests	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Nathalie Dumarcet	Expert	France	No interests declared	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Gabriela Ullio-Gamboa	Expert	France	No interests declared with information under any other interests	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Nathalie Morgensztejn	Expert	France	No interests declared	2.4.1 - Beremagene geperpavec - PRIME - Orphan
Martina Schüßler-Lenz	Expert	Germany	No interests declared with information under any other interests	2.3.1. - Fidanacogene elaparvovec - PRIME
Anna Vikerfors	Expert	Sweden	No interests declared with information under any other interests	5.2.2.

10. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:

List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA's regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation

is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/